TrialRheumatology (Oxford, England)2023

Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study.

Tae-Hwan Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.